TerminatedPhase 3NCT03615924
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- Anders Berggren, MD, PhDAstraZeneca
- Intervention
- Ticagrelor(drug)
- Enrollment
- 193 enrolled
- Eligibility
- 2-17 years · All sexes
- Timeline
- 2018 – 2020
Study locations (30)
- Research Site, Fort Lauderdale, Florida, United States
- Research Site, Miami, Florida, United States
- Research Site, Chicago, Illinois, United States
- Research Site, Oak Lawn, Illinois, United States
- Research Site, Las Vegas, Nevada, United States
- Research Site, Brooklyn, New York, United States
- Research Site, Charleston, South Carolina, United States
- Research Site, Brussels, Belgium
- Research Site, Edegem, Belgium
- Research Site, Porto Alegre, Brazil
- Research Site, Rio de Janeiro, Brazil
- Research Site, Salvador, Brazil
- Research Site, São Paulo, Brazil
- Research Site, Al Sharkeya, Egypt
- Research Site, Alexandria, Egypt
- +15 more locations on ClinicalTrials.gov
Collaborators
Iqvia Pty Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03615924 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi